Literature DB >> 931203

Use of calcium and secretin in the diagnosis of gastrinoma (Zollinger-Ellison syndrome).

C W Deveney, K S Deveney, B M Jaffe, R S Jones, L W Way.   

Abstract

Sixty-five patients with peptic ulcer disease were evaluated for gastrinoma (Zollinger-Ellison syndrome) by measuring changes in serum gastrin concentration after intravenous (i.v.) administration of calcium or secretin, or both. The presence of gastrinoma was established in all 20 patients whose serum gastrin increased by 395 pg/ml or more after i.v. calcium and in all 18 patients whose serum gastrin concentration increased by 110 pg/ml or more after i.v. secretin. The experience with these 65 patients shows that stimulation by calcium or secretin may confirm the presence of gastrinoma in cases where the diagnosis would otherwise remain obscure. Although a positive response to calcium or secretin is diagnostic for gastrinoma a negative response does not exclude this diagnosis. Stimulation with secretin is preferred for screening for gastrinoma because it is quicker and more reliable than calcium.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 931203     DOI: 10.7326/0003-4819-87-6-680

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  28 in total

1.  Criteria for the glucagon provocative test in the diagnosis of gastrinoma.

Authors:  Chikashi Shibata; Masayuki Kakyo; Makoto Kinouchi; Naoki Tanaka; Koh Miura; Takeshi Naitoh; Hitoshi Ogawa; Fuyuhiko Motoi; Shinichi Egawa; Tatsuya Ueno; Hiroo Naito; Michiaki Unno
Journal:  Surg Today       Date:  2012-09-16       Impact factor: 2.549

2.  Secretin provocation in normal and duodenal ulcer subjects. Is the gastrin rise in Zollinger-Ellison syndrome paradoxic or exaggeration?

Authors:  C E Brady; S J Utts; J Dev
Journal:  Dig Dis Sci       Date:  1987-03       Impact factor: 3.199

3.  Serum gastrin, calcitonin, and prolactin as markers of multiple endocrine neoplasia syndromes in patients with primary hyperparathyroidism.

Authors:  J R Farndon; J M Geraghty; W G Dilley; S Handwerger; G S Leight
Journal:  World J Surg       Date:  1987-04       Impact factor: 3.352

4.  Failure of cimetidine in Zollinger-Ellison syndrome.

Authors:  J A Ziemniak; M Madura; A J Adamonis; E J Olinger; M Dreyer; J J Schentag
Journal:  Dig Dis Sci       Date:  1983-11       Impact factor: 3.199

5.  Secretin-receptor and secretin-receptor-variant expression in gastrinomas: correlation with clinical and tumoral features and secretin and calcium provocative test results.

Authors:  Scott H Long; Marc J Berna; Michelle Thill; Andrea Pace; Tapas K Pradhan; K Martin Hoffmann; Jose Serrano; Robert T Jensen
Journal:  J Clin Endocrinol Metab       Date:  2007-08-21       Impact factor: 5.958

6.  Prospective study of gastrinoma localization and resection in patients with Zollinger-Ellison syndrome.

Authors:  J A Norton; J L Doppman; M J Collen; J W Harmon; P N Maton; J D Gardner; R T Jensen
Journal:  Ann Surg       Date:  1986-10       Impact factor: 12.969

7.  Parenteral control of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.

Authors:  R Vinayek; W F Hahne; A R Euler; J A Norton; R T Jensen
Journal:  Dig Dis Sci       Date:  1993-10       Impact factor: 3.199

8.  Serum gastrin responses to bombesin and food in patients with hypergastrinemia.

Authors:  J B Jansen; C B Lamers
Journal:  Dig Dis Sci       Date:  1982-04       Impact factor: 3.199

9.  Serum gastrin response to secretin after vagotomy.

Authors:  M Feldman; J H Walsh; C T Richardson
Journal:  Dig Dis Sci       Date:  1980-12       Impact factor: 3.199

10.  Removal of gastrinomas for control of Zollinger-Ellison syndrome.

Authors:  J W Harmon; J A Norton; M J Collin; A G Krudy; T H Shawker; J L Doppman; J d'Avis; R T Jensen
Journal:  Ann Surg       Date:  1984-10       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.